Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

Next Previous
Trial Profile

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; CD8-TIL cell therapy (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Gastrointestinal cancer; Glioblastoma; Liver cancer; Male breast cancer; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Urogenital cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Jan 2025 Planned End Date changed from 27 Dec 2024 to 27 Dec 2029.
  • 10 Jan 2025 Planned primary completion date changed from 27 Dec 2024 to 27 Dec 2028.
  • 12 Jan 2024 Planned primary completion date changed from 29 Dec 2023 to 27 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top